UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000030917
Receipt number R000035302
Scientific Title The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer
Date of disclosure of the study information 2018/02/15
Last modified on 2019/07/24 09:29:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer

Acronym

The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer (Pre-BICA)

Scientific Title

The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer

Scientific Title:Acronym

The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer (Pre-BICA)

Region

Japan


Condition

Condition

Biliary cancer

Classification by specialty

Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To validate the accuracy of MDCT diagnosis of the pathological TNM stage of biliary cancer, that fulfills the inclusion criteria of the future phase III trial (preoperative therapy + surgery vs. surgery alone) planned in HBP group of Japan Clinically Oncology Group (JCOG)

Basic objectives2

Others

Basic objectives -Others

Validation study

Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

The proportion of pathological stage I (stage IA in distal bile duct cancer) among the patients who were diagnosed with a biliary cancer that fulfills the inclusion criteria of preoperative therapy trial on MDCT

Key secondary outcomes

Sensitivity and specificity of MDCT to diagnose a biliary cancer that fulfills the inclusion criteria of preoperative therapy trial; Sensitivity and specificity of MDCT to diagnose the lymph node metastasis; Sensitivity and specificity of MDCT to diagnose the R1 (invasive cancer) or R2 resection


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who fulfills all the following inclusion criteria
1) The patient is diagnosed with adenocarcinoma of biliary tract by pathological examination of resected or pre-/intra- operative biopsied specimen (The pathological diagnosis is conducted according to the sixth edition of General Rules for the Clinical and Pathological Study of Primary Liver Cancer in intrahepatic bile duct cancer, and according to the sixth edition of Classification of Biliary Tract Cancers in other biliary cancers)
2) The patients who underwent the contrast-enhanced multidetector-row computed tomography (MDCT) examination (5mm or less slice, regardless the presence or absence of biliary drainage) within 60 days before operation, and were diagnosed with resectable biliary cancer (without distant metastasis and R0/1 resection possible)
3) The patients underwent laparotomy with the intent of tumor resection between 2014 and 2016 in the institution of JCOG (including not only the resected cases but also the unresected cases)
4) The patients do not have a past history of either preoperative chemotherapy or radiation therapy in the upper abdomen

Key exclusion criteria

1) The patients with intrahepatic bile duct cancer with the macroscopic appearance of periductal infiltrating type, intraductal-growth type or predominant type of either, because General Rules for the Clinical and Pathological Study of Primary Liver Cancer is not applied to these types.
2) The patients who underwent preoperative image examination only in other hospital
3) The patents who have other active cancers at the time of operation

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name Kazuaki
Middle name
Last name Shimada

Organization

National Cancer Center Hospital

Division name

Hepatobiliary and Pancreatic Surgery Division

Zip code

104-0045

Address

5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan

TEL

03-3542-2511

Email

kshimada@ncc.go.jp


Public contact

Name of contact person

1st name Satoshi
Middle name
Last name Nara

Organization

National Cancer Center Hospital

Division name

Hepatobiliary and Pancreatic Surgery Division

Zip code

104-0045

Address

5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan

TEL

03-3542-2511

Homepage URL


Email

sanara@ncc.go.jp


Sponsor or person

Institute

The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG)

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional review board of National Cancer Center Hospital

Address

5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan

Tel

03-3542-2511

Email

NCC_IRBoffice@ml.res.ncc.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

札幌厚生病院(北海道)
北海道大学病院(北海道)
手稲渓仁会病院(北海道)
東北大学病院(宮城県)
栃木県立がんセンター(栃木県)
自治医科大学(栃木県)
埼玉県立がんセンター(埼玉県)
国立がん研究センター東病院(千葉県)
千葉大学医学部(千葉県)
国立がん研究センター中央病院(東京都)
神奈川県立病院機構神奈川県立がんセンター(神奈川県)
横浜市立大学附属市民総合医療センター(神奈川県)
新潟県立がんセンター新潟病院(新潟県)
富山大学附属病院(富山県)
金沢大学医学部(石川県)
静岡県立静岡がんセンター(静岡県)
大阪国際がんセンター(大阪府)
国立病院機構大阪医療センター(大阪府)
関西医科大学附属病院(大阪府)
兵庫医科大学(兵庫県)
兵庫県立がんセンター(兵庫県)
山口大学医学部附属病院(山口県)
国立病院機構四国がんセンター(愛媛県)
国立病院機構九州がんセンター(福岡県)


Other administrative information

Date of disclosure of the study information

2018 Year 02 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

1237

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 11 Month 30 Day

Date of IRB

2017 Year 12 Month 14 Day

Anticipated trial start date

2017 Year 12 Month 26 Day

Last follow-up date

2018 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is a multi-institutional retrospective observational study


Management information

Registered date

2018 Year 01 Month 21 Day

Last modified on

2019 Year 07 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000035302


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name